Vacuum Conveying In The Pharmaceutical Industry - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Vacuum Conveying In The Pharmaceutical Industry

Pharmaceutical Technology Europe
Volume 22, Issue 8

Sharon Nowak
Pneumatic conveying via vacuum has been used in the pharmaceutical industry for some time now. What are the newest trends in conveying of pharmaceutical powders and blends?

It is true that powder transfer via vacuum has been in use in the pharmaceutical industry for many years. Obviously, vacuum, (usually via dilute phase) has been the transfer mode of choice because of its inherent ability to keep the powder contained within the system due to the suction created by the vacuum. This is in contrast to positive pressure conveying, which is often used in other industries for high volume and long distances. Positive pressure systems have the disadvantage of possible outward leakage, particularly in cases of improperly aligned or incorrectly installed pipework.

Newer trends in conveying involve dense phase vacuum transfer for pre-blends and granulations, specialty designs for containment and cleaning, and the increased use of specially designed pneumatic receivers for refill operations for continuous pharmaceutical processes, such as continuous granulation, mixing/blending, and extrusion.

What are the differences between dense phase and dilute phase conveying?

Figure 1
Dilute phase conveying is typically used with materials where segregation or attrition in the conveying line is not a concern. Comparative gas/air velocities in a 3 inch pipe for dilute phase can range from 15.2 up to 35.6 m/sec (3000 to 7000 ft/min). In dense phase operations (Figure 1), a reduced gas velocity range of 0.4 to 8.6 m/sec (80 to 1700 ft/min) is utilised. In most applications the gas is air, however, in the pharmaceutical industry nitrogen is also widely used because of its inert nature, as well as the natural purity of the gas.

By definition, dense phase means a higher product to gas ratio, in other words a smaller amount of gas is used to move a larger quantity of product. The less gas required for transfer, the lower the power consumption of the exhauster or vacuum pump. Typically material is picked up from the outlet of a specialty hopper, which minimises the amount of air entrained in the material, and allows the slugs of product to form. In addition, the hopper also includes a type of make-up air inlet, which aids in forming the slugs as the material enters the conveying line. The combination of a relatively low air velocity and an expanded line size result in a "siphon-like" effect, transporting the material to the vacuum receiver.

The lower gas velocity used in dense phase conveying results in a much gentler action, reducing wear on the conveyed powder or granulate. This gentle action also reduces the segregation issues often experienced with the more aggressive dilute phase operation, making it ideal for the conveying of powder blends to tabletting machines or roller compactors. It should be noted, however, that there are limitations to the application of dense phase vacuum conveying; for example, conveying distances may not exceed 3.7 m (12 ft) vertical and 4.6 m (15 ft) horizontal. Also, dense phase conveying is not appropriate for conveying materials that are cohesive, hygroscopic or so coarse in particle size that they will not readily form slugs. While dilute phase vacuum conveying is fairly forgiving, dense phase is very dependent on the material characteristics; therefore it is highly advisable to perform full-scale tests when modeling a dense phase vacuum system.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology Europe,
Click here